Latest News

Veryan Presents Two-Year Results from Randomised Controlled Study of BioMimics 3D® Stent at New Cardiovascular Horizons Conference.

New Orleans, 30th May 2014 – Seroba Kernel investee company, Veryan, presented Full two-year data from the Mimics study at the 15th Annual New Cardiovascular Horizons (NCVH) Conference in New Orleans. The data confirmed that BioMimics 3D™ provides a significant improvement in long-term patency compared to a straight nitinol control stent in patients undergoing femoropopliteal...


Covagen Initiates Phase Ib/IIa Study of Bispecific anti-TNF/IL-17A FynomAb COVA322.

ZURICH-SCHLIEREN, Switzerland, May 5, 2014 – Seroba Kernel investee company, Covagen, today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor. COVA322 is Covagen's lead bispecific FynomAb developed for treatment of patients with rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. The trial will enroll 39...


Seroba Kernel and venBio co-lead $20m Investment in Heart Metabolics

Company Established in Ireland as Part of the Financing. DUBLIN – April 17, 2014 – Heart Metabolics Limited, a new Irish biotechnology company focused on the development of drugs for cardio-metabolic diseases, has announced the completion of a $20 million Series A financing co-led by venBio (USA), and Seroba Kernel Life Sciences (Ireland), with additional...


< back to home page